Skip to main content
Premium Trial:

Request an Annual Quote

Henry Schein to Distribute Cepheid GeneXpert in the US

NEW YORK (GenomeWeb) – Cepheid has signed a non-exclusive distribution agreement with Henry Schein Medical — the US health care products and services business of Henry Schein, Inc. — for the GeneXpert molecular diagnostics system and associated tests, the company announced today. Terms of the deal were not disclosed

The agreement focuses on the GeneXpert and test portfolio, including an influenza and respiratory syncytial virus assay that was CLIA waived in December. It expands distribution of the GeneXpert platform and menu of 17 Xpert tests beyond the traditional hospital lab space, according to Cepheid.

"Our relationship with Henry Schein opens an immediate opportunity for GeneXpert System placements in more than 10,000 moderately complex labs outside the hospital," said Cepheid's Chief Medical and Technology Officer David Persing in a statement.  

The non-acute care lab market reached by the Henry Schein distribution network includes physicians’ office labs, women’s health clinics, urgent care facilities, community health centers, correctional facilities, student health centers, STD clinics, long-term care facilities, and reference labs.

Henry Schein will also distribute Cepheid's point-of-care molecular platform, the GeneXpert Omni, subject to US Food and Drug Administration approval of the new platform and associated tests. The firm anticipates launching the Omni in late 2016, with Henry Schein providing access to more than 100,000 CLIA-waived physician office laboratories, Persing added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.